Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS
Germany, December 07, 2016 – Neurimmune and TVM Capital Life Science’s latest fund, TVM Life Science Ventures VII, today announced their investment in…